Skip to main content

Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications

Editors: 
Chung-Tsen Hsueh:
Loma Linda University, USA
Delong Liu: New York Medical College, USA

Submission Status: Open   |   Submission Deadline: Ongoing 


Biomarker Research is calling for submissions to our Collection on "Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications." 

This series intends to collect studies on latest developments in new technologies and clinical applications on liquid biopsy, cfDNA, and ctDNA. Discovery and validation of new biomarkers for diagnosis, therapy and prognosis for human diseases are welcome too.

Articles published in the collection have already gone through the systematic peer review process of the journal.

About the collection

Biomarker Research is calling for submissions to our Collection on "Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications."

This series intends to collect studies on latest developments in new technologies and clinical applications on liquid biopsy, cfDNA, and ctDNA. Discovery and validation of new biomarkers for diagnosis, therapy and prognosis for human diseases are welcome too.

Image credit: © [M] Connect world / stock.adobe.com

  1. Chronic lymphocytic leukemia (CLL) is one of the most frequent occurring types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. At present, the molecular mechanis...

    Authors: Wenjie Zhang, Jinlan Long, Peixia Tang, Kaili Chen, Guangyao Guo, Zezhong Yu, Jie Lin, Liping Liu, Rong Zhan and Zhenshu Xu
    Citation: Biomarker Research 2023 11:58
  2. Lung cancer remains the leading cause of cancer mortality worldwide. Early detection of lung cancer helps improve treatment and survival. Numerous aberrant DNA methylations have been reported in early-stage lu...

    Authors: Shuo Hu, Jinsheng Tao, Minhua Peng, Zhujia Ye, Zhiwei Chen, Haisheng Chen, Haifeng Yu, Bo Wang, Jian-Bing Fan and Bin Ni
    Citation: Biomarker Research 2023 11:45
  3. Multiple myeloma (MM) is an incurable hematological cancer with high spatial- and temporal-heterogeneity. Invasive single-point bone marrow sampling cannot capture the tumor heterogeneity and is difficult to r...

    Authors: Shuchan Li, Enfan Zhang and Zhen Cai
    Citation: Biomarker Research 2023 11:27

Submission Guidelines

Back to top

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system. During the submission process you will be asked whether you are submitting to a Collection, please select "Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.